| Expression pattern: |
UP |
| Associated gene: |
VEGF mRNA, VEGF protein |
| Associated microRNA: |
- |
| Biological function: |
circCDYL serves as an up-regulated cancer-associated target for intracellular imaging and as an endogenous trigger for nanolantern-mediated on-demand siRNA release, VEGF gene silencing, and apoptosis induction in cancer cells. |
| Molecular mechanism: |
circCDYL binds the catcher duplex of the nanolantern probe and initiates entropy-driven strand displacement assembly, producing fluorescent nanolantern concatemers and releasing siRNAs that guide RISC-mediated VEGF mRNA silencing. |
| Biological pathway or process: |
apoptosis (promotes); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; ROC Analysis; Transfection; Annexin V/PI Flow Cytometry; Western Blot |
| Clinical significance: |
circCDYL can be accurately quantified to discriminate breast cancer patient tissues from healthy person tissues; ROC analysis showed AUC = 1 for the proposed method and qRT-PCR. |
| Description: |
This study used circCDYL as a cancer-associated target for a DNA nanolantern-based imaging and gene therapy platform. circCDYL was up-regulated in breast cancer tissues and cancer cell lines, and its presence triggered strand-displacement assembly of nanolantern concatemers with on-demand siRNA release to silence VEGF mRNA and induce apoptosis in MCF-7 cells. Clinically, circCDYL quantification by the nanolantern method and qRT-PCR discriminated breast cancer tissues from healthy tissues with high accuracy. |
| Confidence score: |
0.6762 |